StockNews.AI

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

StockNews.AI • 1 minute

TSROABBV
High Materiality8/10

Information

DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today t...

Original source

AI Summary

Tesaro, a GSK subsidiary, has entered a licensing deal with Alteogen for ALT-B4, providing an upfront payment and potential milestone payments. This collaboration focuses on the subcutaneous formulation of dostarlimab, which could improve patient experience and market reach, thereby positively impacting GSK's oncology portfolio.

Sentiment Rationale

Partnerships like this typically drive positive sentiment and potential revenue growth in biotech, evidenced by past successful collaborations that boosted company valuations.

Trading Thesis

GSK appears well-positioned for growth through this partnership; recommend a buy in the near term.

Market-Moving

  • The milestone payments up to $265 million could enhance GSK’s oncology revenue.
  • Successful development of subcutaneous dostarlimab could capture a larger market share.
  • Improved patient administration method may boost prescription rates for dostarlimab.
  • This collaboration could attract investor confidence in GSK’s oncology pipeline.

Key Facts

  • Tesaro, a GSK subsidiary, licensed ALT-B4 from Alteogen.
  • The deal includes a $20 million upfront payment and up to $265 million in milestones.
  • ALT-B4 facilitates subcutaneous delivery of dostarlimab, enhancing its market potential.
  • Alteogen will supply ALT-B4 for the drug’s development and commercialization.
  • This partnership aims to improve patient administration of dostarlimab.

Companies Mentioned

  • Alteogen Inc. (196170.KS): Partnering with GSK’s Tesaro signals innovative advancements in oncology.
  • GSK plc (GSK): Strengthens GSK's oncology portfolio with a new delivery method for dostarlimab.

Corporate Developments

This falls under 'Corporate Developments' as it highlights a strategic licensing agreement that could enhance GSK’s product offerings and market competitiveness in oncology, aligning with current trends in drug delivery innovation.

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK

Alteogen Inc. (KOSDAQ: 196170) has entered into a significant exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. This collaboration will focus on the development of a subcutaneous formulation of dostarlimab, a programmed death receptor-1 (PD-1) blocking antibody, utilizing Alteogen's innovative Hybrozyme™ technology. The announcement took place on [Insert Date], marking a pivotal moment for both companies in the oncology sector.

Details of the Agreement

Under the terms of this agreement, Tesaro will gain worldwide rights to use ALT-B4, which is Alteogen's proprietary hyaluronidase enzyme. The partnership is set to progress through various stages of development and commercialization. Key financial components of the agreement include:

  • Upfront Payment: Alteogen will receive an upfront payment of US$20 million.
  • Milestone Payments: The company is eligible for milestone payments totaling up to US$265 million as specific development, regulatory, and sales milestones are achieved.
  • Royalties: Alteogen will be entitled to royalties on the sales of the finalized product.

Furthermore, Alteogen will manage the clinical and commercial supply of ALT-B4 to Tesaro, reinforcing their role in the product's development.

Implications for Cancer Treatment

Dr. Tae-Yon Chun, CEO of Alteogen, expressed enthusiasm about the collaboration, stating, "We are excited to expand our Hybrozyme™ technology by collaborating with Tesaro in the oncology field, and look forward to developing and bringing this potential subcutaneous medicine to market."

The introduction of ALT-B4 has significant implications for cancer treatment. By enabling large volume subcutaneous administration of drugs traditionally given as IV infusions, ALT-B4 represents a new approach that could enhance patient comfort and compliance.

About ALT-B4 and Hybrozyme™ Technology

ALT-B4 is based on Alteogen's proprietary human recombinant hyaluronidase enzyme developed with Hybrozyme™ technology. This groundbreaking enzyme temporarily hydrolyzes hyaluronan in the extracellular matrix, facilitating efficient drug delivery.

Corporate Overview: Alteogen Inc.

Founded in 2008, Alteogen Inc. is a biopharmaceutical company based in South Korea. The company focuses on the development and commercialization of novel biologics, including Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's diverse portfolio features clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed through its proprietary NexP™-fusion and NexMab™ platform technologies. The company is publicly listed on KOSDAQ under the symbol 196170.KQ.

Contact Information

For further inquiries, please contact:

Vivek Shenoy, Ph.D., MBA
Chief Business Officer
Phone: +1 805 570 8998
E-mail: [email protected]

Related News